SALT LAKE CITY (August 23, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the
use of data analytics for disease identification and subsequent clinical
intervention through precision therapies, announces the appointment of Jeff
Acuff to the newly created position of Chief Commercial Officer of its wholly
owned subsidiary Predictive Biotech.
Mr. Acuff will be responsible for the commercial
strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P)
business, and will implement programs and business development strategies aimed
at driving sales and increasing physician awareness of HCT/P treatment options.
He also will lead the commercial development of new product candidates, and the
expansion and use of the human cell and tissue products into new
vertical-market targets that include wound management and aesthetics. Additionally,
he will oversee the long-term business development strategy for cellular
therapies being developed by Predictive Therapeutics.
“Jeff brings a deep knowledge of the healthcare
industry, a clear focus of physician and patient needs, and a proven track
record of successful execution in ortho-biologic sales, which makes him ideally
suited to lead the commercial efforts for Predictive Biotech, as well as the
development of the Company’s sales expansion plans,” said Mr. Eric Olson, CEO
of Predictive Biotech. “Under his leadership, I am confident we will continue
to build upon the Company’s solid foundation in sales and strengthen our
ability to bring quality products to our physician customers.”
“I am very excited and honored to lead such
a talented and proven team as we continue to focus on building the Company’s
portfolio and capabilities for the future,” said Mr. Acuff. “Predictive Biotech
has made the safety, efficacy and quality of its human cell and tissue products
the number one priority in serving physician customers and their patients. The
Company has delivered over 95,000 allografts to date and is proud to serve as a
reliable, quality manufacturer. I look forward to building upon these trusted customer
relationships to best serve patient needs.”
Mr. Acuff has more than 25 years of commercial
and leadership experience concentrated in the medical device and biologics
industry, and has a proven track record for building high-performing teams and
achieving exceptional results. He most recently served as the Commercial
Excellence Leader for GE Healthcare. Prior to joining GE Healthcare, Mr. Acuff was
Senior Vice President of Sales leading the commercial efforts of Bioventus, a
private equity-owned ortho-biologics company, and was Vice President of Sales,
Americas for Varian Medical Systems, where he helped develop and lead the
commercial strategy and implementation for its radiation oncology business. Before
that, he served for 13 years at Medtronic in various roles, including Vice
President of Sales, Biologics and Vice President of Enabling Technologies Sales
& Marketing. During his tenure at Medtronic, he led sales organizations in
both mature and fast-growing market segments including interventional cardiology,
interventional radiology, endovascular surgery, spine, and biologics.
Mr. Acuff holds a Bachelor of Business
Administration in Management from the University of Memphis and completed an Executive
Program at the Kellogg School of Management at Northwestern University.
About Predictive
Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake
City-based life sciences company formed in 2015, is a leader in human cell and
tissue products for use in cellular therapies and regenerative medicine. A
growing national network of clinics, health systems, researchers and physicians
leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical
cord-derived products. Predictive Biotech’s current products are regulated by
the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts
intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient
care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive Therapeutics,
Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused
on endometriosis, scoliosis, degenerative disc disease, and human cell and
tissue products. The subsidiaries use genetic and other information as
cornerstones in the development of new diagnostics that assess a person’s risk
of illness and therapeutic products designed to identify, prevent and treat
diseases more effectively. Additional information is
available at Predtechgroup.com, Predrx.com, Predictivebiotech.com,
and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information,
visit www.predtechgroup.com
Contacts:For more information, visit www.predtechgroup.com Relations:
Covalent Collective, Inc. Announces Dismissal of US SEC Enforcement Action
/in Covalent Collective, Inc., Press Releases /by Yes InternationalCOLORADO SPRINGS, CO-September 4, 2019 – Covalent Collective, Inc. (the “Company”), a burgeoning network of vertically integrated cannabis-centric enterprises, announces that the United States Securities and Exchange Commission (US SEC) has dismissed its subpoena enforcement action against the Company.
On October 24, 2018, the US SEC issued a subpoena against the Company requiring the production a variety of documents in the Company’s possession, custody or control. On August 15, 2019, the SEC reported to the presiding Judge in the enforcement action that it had received all the subpoenaed documents, and Case No. 1:19−cv−03721 in the United States District Court for the Northern District of Illinois, Eastern Division, was dismissed. To view the case file follow the following link: Case No. 1:19−cv−03721. This will take you the the SEC’s recently filed cases. You will need to register for a PACER account in order to view the official documents.
“When we submitted our document production on July 23, 2019, we were confident that we had provided everything necessary to comply with the SEC’s subpoena,” commented Mr. Bill Gregorak, CEO of Covalent Collective. “It is gratifying to have received confirmation from the SEC and we are happy to be able to put this issue behind us and move forward with our corporate strategy of acquiring assets in our geographic priorities.”
About Covalent Collective:
Covalent Collective, Inc. is a British Columbia, Canada company founded in 2014 and headquartered in Colorado Springs, CO. The Company is building a diverse network of vertically integrated cannabis-centric enterprises that span the entirety of the legal cannabis and hemp industries. With a vision to build the largest grow capacity in the U.S., Covalent Collective’s mission is to create stronger bonds throughout the greater cannabis community through the execution of an acquisition and joint venture strategy that is strategically positioned to support eventual federal legalization in the United States. For more information, please visit https://covalentcannabis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements with respect to the Company’s acquisition strategies. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statements in this press release, and readers should not place undue reliance on any such forward-looking statements since they are not guarantees of future results. The Company does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
Investor Contact:
Richard Kaiser
Collective, Inc.
rkaiser@covalentcannabis.com
757-306-6090
ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES ELEMENT MEDIA GROUP ENTERING INTO “MOU” WITH LIVIT MEDIA, INC.
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- September 3, 2019- Element Global, Inc (ELGL: OTCMARKETS) announces that its wholly-owned subsidiary, Element Media Group, Inc, entered into a binding Memorandum of Understanding (“MOU”) with Livit Media, Inc., www.livitnow.com.
Adam Blazer, www.adamblazer.com, an accomplished American entrepreneur with experience in broadcast and cable television, production, and immersive media strategy including AR (Augmented Reality), expects Livit Media, Inc. to be a key technology partner with Element Media Group, Inc.
Under Mr. Blazer’s leadership as Livit’s founder and CEO, the company became a trusted developer of AR and VR (Virtual Reality) experiences and platforms. Using its proprietary technologies, Livit manages XR (Extended Reality) campaigns for the world’s biggest brands and businesses in sports, entertainment, fashion and enterprise.
Livit has worked with Wimbledon, US Open, Fox Sports YES, HBO, Christian Dior, Moschino, and others. In 2016, Livit Media, Inc. launched the world’s first 360-VR Mobile streaming platform.
Mr. Blazer has joined the Senior Advisory Board of Element Media Group.
About Element Global Inc.
Element Global, Inc. (ELGL: OTCMARKETS), a diversified holding company with global business interests centered on renewable energy, technology, media and production, distribution and AVOD/SVOD streaming on its platform in original and licensed film and TV content globally, brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, which supports emission reductions through the electrification of power, transport, industry, and buildings, ELGL envisions itself capitalizing on the increases in demand in these industries.
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES ELEMENT MEDIA GROUP ENTERING INTO “MOU” WITH PASSPORT NETWORKS
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- August 20, 2019- Element Global, Inc (ELGL: OTCMARKETS) announces that its wholly-owned subsidiary, Element Media Group, Inc, entered into a binding Memorandum of Understanding (“MOU”) with Passport Networks.
Passport Networks, a unique Over the Top (OTT) platform, anticipates to provided original created and curated content for ex-pat communities. Passport expects to deliver curated content that connects communities to their cultural roots and centralizes global information, culture, and entertainment. Currently, negotiations on retransmission licensing and library content agreements should give Passport Networks access to foreign news, sports, cinema, documentary and lifestyle content to viewers.
Element Media Group, Inc. and Passports Networks expect to develop a comprehensive and strategic content and co-production partnerships.
About Element Global, Inc.
Element Global, Inc. (ELGL: OTCMARKETS), a diversified holding Company with global business interests centered on renewable energy, technology, media and production, distribution and streaming in original and licensed film and TV content globally, brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, supporting emission reductions through the electrification of power, transport, industry, and buildings, ELGL envisions itself capitalizing on the increases in demand in these industries.
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES ELEMENT MEDIA GROUP ENTERING INTO “MOU” WITH PORTAL HOUSE, LLC.
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- August 20, 2019- Element Global, Inc (ELGL:OTCMARKETS) announces that its wholly-owned subsidiary, Element Media Group, Inc, entered into a binding Memorandum of Understanding (“MOU”) with Portal House, LLC, www.portal-house.com.
Co-Founder of Portal House, LLC, Daniel Shemtob, www.danielshemtob.com, a Los Angeles, California based entrepreneur with several successful hospitality businesses, derived the vision for Portal House as a platform for the next generation of producers and artists, and a destination for patrons of the arts and technology enthusiasts.
Portal House creates a space where artistic expression, technological innovation, and audience participation collide. The business recruits artists who are interested in or who have created technology-driven work. They then pair the artists with technologists, engineers, programmers, and fabricators to make the artists’ creative visions come to life. Portal House expects to provide Element Media Group, Inc. a robust network of international talent.
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
PREDICTIVE TECHNOLOGY GROUP NAMES BIOLOGIC INDUSTRY LEADER JEFF ACUFF AS CHIEF COMMERCIAL OFFICER OF PREDICTIVE BIOTECH
/in Predictive Technology Group, Press Releases /by Yes InternationalSALT LAKE CITY (August 23, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces the appointment of Jeff Acuff to the newly created position of Chief Commercial Officer of its wholly owned subsidiary Predictive Biotech.
Mr. Acuff will be responsible for the commercial strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P) business, and will implement programs and business development strategies aimed at driving sales and increasing physician awareness of HCT/P treatment options. He also will lead the commercial development of new product candidates, and the expansion and use of the human cell and tissue products into new vertical-market targets that include wound management and aesthetics. Additionally, he will oversee the long-term business development strategy for cellular therapies being developed by Predictive Therapeutics.
“Jeff brings a deep knowledge of the healthcare industry, a clear focus of physician and patient needs, and a proven track record of successful execution in ortho-biologic sales, which makes him ideally suited to lead the commercial efforts for Predictive Biotech, as well as the development of the Company’s sales expansion plans,” said Mr. Eric Olson, CEO of Predictive Biotech. “Under his leadership, I am confident we will continue to build upon the Company’s solid foundation in sales and strengthen our ability to bring quality products to our physician customers.”
“I am very excited and honored to lead such a talented and proven team as we continue to focus on building the Company’s portfolio and capabilities for the future,” said Mr. Acuff. “Predictive Biotech has made the safety, efficacy and quality of its human cell and tissue products the number one priority in serving physician customers and their patients. The Company has delivered over 95,000 allografts to date and is proud to serve as a reliable, quality manufacturer. I look forward to building upon these trusted customer relationships to best serve patient needs.”
Mr. Acuff has more than 25 years of commercial and leadership experience concentrated in the medical device and biologics industry, and has a proven track record for building high-performing teams and achieving exceptional results. He most recently served as the Commercial Excellence Leader for GE Healthcare. Prior to joining GE Healthcare, Mr. Acuff was Senior Vice President of Sales leading the commercial efforts of Bioventus, a private equity-owned ortho-biologics company, and was Vice President of Sales, Americas for Varian Medical Systems, where he helped develop and lead the commercial strategy and implementation for its radiation oncology business. Before that, he served for 13 years at Medtronic in various roles, including Vice President of Sales, Biologics and Vice President of Enabling Technologies Sales & Marketing. During his tenure at Medtronic, he led sales organizations in both mature and fast-growing market segments including interventional cardiology, interventional radiology, endovascular surgery, spine, and biologics.
Mr. Acuff holds a Bachelor of Business Administration in Management from the University of Memphis and completed an Executive Program at the Kellogg School of Management at Northwestern University.
About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information, visit www.predtechgroup.com
Contacts:For more information, visit www.predtechgroup.com Relations:
ELEMENT GLOBAL, INC’s (ELGL) SUBSIDIARY ELEMENT GLOBAL MINING ENTERPRISES ANNOUNCES STRATEGIC PLAN
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- August 22, 2019- Element Global Mining Enterprises, a wholly-owned subsidiary of Element Global Inc. (ELGL: OTCMARKETS), announces the focus of the Company and its overall strategic direction.
Increasing demand for lithium-ion batteries, driven predominantly by electric vehicles and energy storage systems, coupled with the introduction of “Mineral Security Legislation” in the US, creates an opportunity to launch a specialist battery materials provider into the fragmented and generally under-capitalized North American market. Element Global Mining (“EGM”) intends to capitalize on these developments by focusing its business on “electric metals,” initially copper and manganese, before expanding into other battery minerals, and on creating a US domestic supply chain.
Gary Lewis, CEO states, “While the temptation will always exist to stray into other jurisdictions and other minerals, ‘EGM’ remains disciplined and centered on these important tenets to establish and maintain a competitive advantage. Acquiring and investing in multiple projects across several battery-related commodities provides ample growth opportunities, while mitigating risk with focusing the business in the US.”
In addition to the copper assets owned by Element’s subsidiary Clarinova Limited, “EGM” continues forward with the final stage of transacting on many other high-quality, US-domiciled projects. Firmly within the Company’s strategic plan, the market can expect announcements on these transactions in coming weeks, along with a world-class technical team being assembled to grow and advance the Company’s portfolio of “electric metals”.
About Element Global Inc
Element Global, Inc (ELGL: OTCMARKETS), a diversified holding Company with global business interests centered on renewable energy, technology, media and production, distribution and streaming in original and licensed film and tv content globally, brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, supporting emissions reductions through the electrification of power, transport, industry and buildings, ELGL’s visions itself to capitalize on the increases in demand in these industries.
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC. (ELGL) NAMES INDUSTRY VETERAN MR. GARY L. LEWIS AS BOARD OF DIRECTOR AND CEO OF WHOLLY-OWNED SUBSIDIARY, ELEMENT GLOBAL MINING, INC.
/in Uncategorized /by Yes InternationalLos Angeles, CA- August 20, 2019- Element Global, Inc. (OTCMARKETS: ELGL) announces that Mr. Gary L. Lewis joined the Company as a Director and became the Chief Executive Officer of Element Global Mining, Inc., a wholly-owned Subsidiary.
Mr. Lewis holds a Bachelor of Commerce and Masters of Business & Technology (MBT) from the University of New South Wales, Sydney, Australia. With over 30-years experience in international capital markets and business and strategy development, he has founded, financed and/or operated resource projects or assets valued at more than US$400m, including the acquisition and ultimate sell-down or listing of high-value, multi-commodity resource projects in Australia, Asia and the Americas. Mr. Lewis has held numerous senior executive board positions in companies listed on Toronto Stock Exchange (TSX), Australian Securities Exchange (ASX) and the London Stock Exchange (AIM).
Mr. Lewis was most recently the founder and Managing Director of Battery Mineral Resource Limited (BMR), a battery mineral explorer and developer which focused on cobalt, lithium and graphite in Canada, USA and South Korea. Since July 2016, he worked to acquire over 9,000 mineral tenements in Canada and the USA, creating the largest landholding of high-grade cobalt in North America. In addition to cobalt, he created North America’s largest lithium brine exploration project in the western USA and acquired South Korea’s largest and only NI 43-101 compliant graphite resource.
Prior to BMR, Mr. Lewis founded Robust Resources Limited (Robust), an ASX-listed mineral explorer and developer that focused on precious and base metals and manganese in Australia, Indonesia, and the Philippines. As Managing Director, he propelled Robust to become the second-best performing company on the ASX in 2009 and 2010, before privatizing the Company in 2014.
As a founder and Executive Chairman of Tengri Resources, he acquired multi-million-ounce precious metal and multi-billion pound copper holdings throughout Central Asia before listing the Company on AIM (UK).
Merle Ferguson, Chairman, ELGL, states, “We welcome Mr. Lewis to the ELGL team to support our goal of commercializing our mining assets. He is a highly accomplished in the development and commercialization of mining assets around the world. His experience and commitment to delivering results will be of tremendous assistance in supporting the Company’s expected successes.”
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
PREDICTIVE TECHNOLOGY GROUP ACCELERATES RESEARCH SAMPLE COLLECTIONS TO SUPPORT DEVELOPMENT OF PERSONALIZED MOLECULAR DIAGNOSTICS AND CLINICAL THERAPIES
/in Predictive Technology Group, Press Releases /by Yes InternationalSubsidiary Predictive Laboratories hits milestone with 2,500 samples collected and processed since acquiring CLIA operations in March 2019; four new research sample collection initiatives set to begin this quarter
SALT LAKE CITY (August 20, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories™ has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. Predictive is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility.
Research is conducted following strict protocols approved by external Institutional Review Boards. Hundreds of individuals each month have voluntarily consented to share their medical histories and DNA samples for ongoing research. All research subjects are informed that their samples will be used in aggregate to develop new commercial diagnostic and therapeutic products. To ensure privacy, research samples and datasets are deidentified and securely stored.
Personalized medicine and the development of new therapeutics are expected to play a critical role in human health. Access to high-quality biospecimens from Predictive’s biobank will be crucial for furthering the Company’s biomedical and translational research, and ultimately its development of personalized molecular diagnostics and clinical therapies. Current sample collection efforts are designed to strategically augment Predictive’s existing library of over 300,000 DNA samples that the Company believes will produce valuable insights into future research and development projects.
The development of effective diagnostic and treatment products requires identification of genetic markers that are useful for early detection, prevention, and personalized treatment of specific medical conditions. Genetic discoveries lead to insights into the cause and progression of disease and often suggest novel means of treating serious chronic conditions. Modern genetic research requires large numbers of well-characterized samples; one set for discovery, another independent set for replication, a third for validation, and a fourth to prove the clinical utility.
“The ability to discover specific genetic markers related to the diagnosis, prognosis, and therapeutic response for disease targets can help Predictive find solutions that could transform medical care,” said Bradley Robinson, CEO of Predictive Technology Group. “A crucial requirement for personalized medicine is the availability of an extensive collection of both human diseased and healthy samples with well-documented medical records.
“Through investment in our biobank initiatives and collaboration with others who have relevant research collections, we reached this new collection milestone of 2,500 samples very rapidly and we continue to build on our database,” he added. “At Predictive Laboratories, we have state-of-the-art capabilities for automated DNA extraction, sample handling, and high-throughput genotyping and sequencing that support our planned development of breakthrough diagnostics and therapeutics.”
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
ELEMENT GLOBAL, INC’s (ELGL) SUBSIDIARY CLARINOVA TO START MINING FEASIBILITY STUDY
/in Element Global, Inc., Press Releases, Uncategorized /by Yes InternationalLos Angeles, CA- August 15, 2019- Clarinova Limited, a wholly-owned subsidiary of Element Global Inc. (ELGL: OTCMARKETS), announces the beginning to undertake a NI 43-101 geological feasibility survey of its audited mining tailing assets.
The plan calls for Clarinova Limited to utilize the resources of Element Global Mining Enterprises, Inc., the wholly-owned mining subsidiary of Element Global, Inc. to undertake the technical survey and testing starting this September 2019.
“NI 43-101 Standards” is a Canadian National Instrument for the “Standards of Disclosures for Mineral Projects.” The reports defined the mineral resources and mineral reserves on mining projects and properties. Each of these terms is divided into subcategories based on the quality and amount of work done to verify the amounts of minerals available and the economic viability of extracting them. A mineral resource is defined as a concentration or occurrence of minerals in such form and quantity and of such grade or quality that it has reasonable prospects for economic extraction. The three different types of mineral resources are metallic, nonmetallic and fossil fuels.
Merle Ferguson, Chairman, states, “Getting our project to a 43-101 standard provides the Company with a bankable feasibility of the economic values of the mineral tailings held in Clarinova Ltd.”
Even though ELGL is a US entity which trades in the US, it is producing a bankable feasibility study to the qualification and quantification of the internationally recognized Canadian NI 43-101 standards, which remains an essential validation of the content and values of both precious and base metals in the mineralized tailings. Moreover, if the Company should decide to dual-list its equity on a Canadian stock exchange or perhaps the London Stock Exchange, the feasibility would facilitate such a listing.
For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC. (ELGL) ACQUIRES CLARINOVA LIMITED
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- August 13, 2019- Element Global, Inc. ( ELGL: OTCMARKETS) announces its acquisition of Clarinova Limited.
Clarinova Limited owns historic tailing piles. These tailing piles based on today’s precious and semi-precious metal prices can be considered commercial grades and values.
Based on the terms of the agreement, Clarinova Limited, as a wholly-owned subsidiary, will act as the finance, treasury, and private equity arm for all of Element Global’s operations and subsidiaries. Mr. Bertil Olsson remains Chairman of the Clarinova Limited subsidiary, and is now a member of the Board of Directors of the parent company, ELGL.
Merle Ferguson, Chairman of Element Global, Inc., states: “After three years of negotiations and due diligence, the acquisition of Clarinova Limited as a wholly-owned subsidiary brings an enormous value-added asset to ELGL.“
He further states: “Given the recent increases in precious metal prices based on world demand as investors seek safe-haven assets during times of uncertainty, the timing of the Clarinova acquisition could not be better.”
At the time of publication of this release, prices for GOLD per ounce $1495.00 US, Silver per ounce $16.83 US, and Copper per pound $2.61 US.
ELGL expects to hire qualified mining executives into the Element Global Mining Enterprises subsidiary with one of their main focuses being a detailed audit and plan for the monetization of Clarinova Limited’s Battery Mineral related assets which also includes copper, gold and silver.
For further information about this release contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.